دورية أكاديمية
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
| العنوان: | Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. |
|---|---|
| المؤلفون: | Stecklein SR; University of Kansas Medical Center, Kansas City, KS., Barlow W; SWOG Statistical Center, Seattle, WA., Pusztai L; Yale Cancer Center, New Haven, CT., Timms K; Myriad Genetics, Inc, Salt Lake City, UT., Kennedy R; Almac Diagnostic Services, Craigavon, Northern Ireland, United Kingdom.; Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, United Kingdom., Logan GE; Almac Diagnostic Services, Craigavon, Northern Ireland, United Kingdom., Seitz R; Oncocyte, Irvine, CA., Badve S; Emory University School of Medicine, Atlanta, GA., Gökmen-Polar Y; Emory University School of Medicine, Atlanta, GA., Porter P; Fred Hutchinson Cancer Center, Seattle, WA., Linden H; Fred Hutchinson Cancer Center, Seattle, WA., Tripathy D; MD Anderson Cancer Center, Houston, TX., Hortobagyi GN; MD Anderson Cancer Center, Houston, TX., Godwin AK; University of Kansas Medical Center, Kansas City, KS., Thompson A; Baylor College of Medicine, Houston, TX., Hayes DF; University of Michigan, Ann Arbor, MI., Sharma P; University of Kansas Medical Center, Kansas City, KS. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2023 Sep; Vol. 7, pp. e2300197. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Triple Negative Breast Neoplasms*/diagnosis , Triple Negative Breast Neoplasms*/genetics , Triple Negative Breast Neoplasms*/drug therapy, Humans ; Prognosis ; Homologous Recombination/genetics ; DNA Damage/genetics ; Immunity ; Tumor Microenvironment |
| مستخلص: | Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease. We previously showed that homologous recombination deficiency (HRD) and the DNA damage immune response (DDIR) signature are prognostic in TNBC. We hypothesized that these biomarkers reflect related but not completely interdependent biological processes, that their combined use would be prognostic, and that simultaneous assessment of the immunologic microenvironment and susceptibility to DNA damaging therapies might be able to identify subgroups with distinct therapeutic vulnerabilities. Methods: We analyzed the dual DDIR/HRD classification in 341 patients with TNBC treated with adjuvant anthracycline-based chemotherapy on the SWOG S9313 trial and corroborated our findings in The Cancer Genome Atlas breast cancer data set. Results: DDIR/HRD classification is highly prognostic in TNBC and identifies biologically and immunologically distinct subgroups. Immune-enriched DDIR+/HRD+ TNBCs have the most favorable prognosis, and DDIR+/HRD- and DDIR-/HRD+ TNBCs have favorable intermediate prognosis, despite the latter being immune-depleted. DDIR-/HRD- TNBCs have the worst prognosis and represent an internally heterogeneous group of immune-depleted chemoresistant tumors. Conclusion: Our findings propose DDIR/HRD classification as a potentially clinically relevant approach to categorize tumors on the basis of therapeutic vulnerabilities. |
| References: | Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935) Clin Cancer Res. 2021 Feb 15;27(4):975-982. (PMID: 33208340) Cancer. 2007 May 1;109(9):1721-8. (PMID: 17387718) J Natl Cancer Inst. 2016 Oct 5;109(1):. (PMID: 27707838) J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45. (PMID: 9701363) Ann Oncol. 2018 Mar 1;29(3):654-660. (PMID: 29293876) Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877) Nat Commun. 2021 Nov 1;12(1):6276. (PMID: 34725325) Cancer Res. 2010 Apr 15;70(8):3052-61. (PMID: 20388795) Cancer Cell. 2022 Jun 13;40(6):609-623.e6. (PMID: 35623341) Adv Cancer Res. 1997;71:27-92. (PMID: 9111863) Histopathology. 2020 Aug;77(2):181-185. (PMID: 32056259) N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663) Nat Biotechnol. 2019 Jul;37(7):773-782. (PMID: 31061481) Cancer. 1996 Feb 15;77(4):697-709. (PMID: 8616762) Nat Med. 2007 Jan;13(1):54-61. (PMID: 17187072) Transl Res. 2012 Sep;160(3):178-97. (PMID: 22683426) Cell Death Differ. 2014 Jan;21(1):69-78. (PMID: 23811849) Cell Death Dis. 2015 Jun 18;6:e1792. (PMID: 26086965) Br J Cancer. 2022 Feb;126(2):247-258. (PMID: 34728791) J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4. (PMID: 16106022) Cell Death Differ. 2014 Jan;21(1):79-91. (PMID: 23852373) J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045) J Natl Cancer Inst. 2015 Mar 30;107(6):djv048. (PMID: 25825511) Cancer Res. 2012 Nov 1;72(21):5454-62. (PMID: 22933060) Breast Cancer Res. 2017 Aug 25;19(1):99. (PMID: 28851423) N Engl J Med. 2022 Feb 10;386(6):556-567. (PMID: 35139274) J Natl Cancer Inst. 2014 Jan;106(1):djt335. (PMID: 24402422) Br J Cancer. 2012 Nov 6;107(10):1776-82. (PMID: 23047548) Lancet Oncol. 2020 Jan;21(1):44-59. (PMID: 31786121) PLoS One. 2016 Jun 16;11(6):e0157368. (PMID: 27310713) Oncogene. 2007 Nov 15;26(52):7283-301. (PMID: 17533367) Cancer Metastasis Rev. 2011 Mar;30(1):61-9. (PMID: 21249425) Lancet. 2020 Oct 10;396(10257):1090-1100. (PMID: 32966830) Nature. 2017 Aug 24;548(7668):461-465. (PMID: 28738408) Cancers (Basel). 2020 Dec 08;12(12):. (PMID: 33302444) Cancer Cell. 2015 Dec 14;28(6):690-714. (PMID: 26678337) Cancer Discov. 2012 Apr;2(4):366-375. (PMID: 22576213) J Oncol Pract. 2010 Jul;6(4):195-7. (PMID: 21037871) Nat Commun. 2017 Nov 24;8(1):1751. (PMID: 29170499) Nat Commun. 2020 May 29;11(1):2662. (PMID: 32471999) J Clin Oncol. 2019 Dec 20;37(36):3484-3492. (PMID: 31657982) |
| معلومات مُعتمدة: | UL1 TR001863 United States TR NCATS NIH HHS; UG1 CA233160 United States CA NCI NIH HHS; P20 GM130423 United States GM NIGMS NIH HHS; U10 CA180888 United States CA NCI NIH HHS; U10 CA180819 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20231116 Date Completed: 20231120 Latest Revision: 20240708 |
| رمز التحديث: | 20240708 |
| مُعرف محوري في PubMed: | PMC10681491 |
| DOI: | 10.1200/PO.23.00197 |
| PMID: | 37972336 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO.23.00197 |